Clinical Trials Directory

Trials / Completed

CompletedNCT01329380

Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)

Special Investigation (All Cases Investigation in Patients With Ankylosing Spondylitis)

Status
Completed
Phase
Study type
Observational
Enrollment
403 (actual)
Sponsor
AbbVie · Industry
Sex
All
Age
16 Years – 99 Years
Healthy volunteers
Not accepted

Summary

This study of adalimumab (Humira) will be conducted to clarify the following with regard to the treatment of ankylosing spondylitis with this drug: * Unknown adverse drug reactions (especially important adverse drug reactions) * Incidence and conditions of occurrence of adverse reactions in the clinical setting * Factors that may affect the safety and effectiveness of Humira

Conditions

Timeline

Start date
2010-10-27
Primary completion
2017-12-28
Completion
2017-12-28
First posted
2011-04-05
Last updated
2019-04-03
Results posted
2019-04-03

Locations

194 sites across 1 country: Japan

Source: ClinicalTrials.gov record NCT01329380. Inclusion in this directory is not an endorsement.

Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation) (NCT01329380) · Clinical Trials Directory